Construction of recombinant newcastle disease virus Italien strain for oncolytic virotherapy of tumors

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 700-710

  Wei, Ding ^a   Sun, Na ^a   Nan, Gang ^a   Wang, Yuan ^a   Liu, Hong Qi ^a   Peeters, Ben ^b   Chen, Zhi Nan ^a   Bian, Huijie ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FIREFLY LUCIFERASE; INTERFERON; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC PARAMYXOVIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SENSITIVITY; GENE INSERTION; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NEWCASTLE DISEASE VIRUS ITALIEN; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; REPORTER GENE; REVERSE GENETICS; SURVIVAL; SYNCYTIUM; VIRULENCE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; WEIGHT REDUCTION;

ANIMALS; CELL SURVIVAL; CLONING, MOLECULAR; FEMALE; GENES, REPORTER; GIANT CELLS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; INTERFERONS; LUCIFERASES, FIREFLY; MICE; MICE, NUDE; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REVERSE GENETICS; TUMOR BURDEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; NEWCASTLE DISEASE VIRUS;

EID: 84864361780     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.207     Document Type: Article

References (30)

1. Altomonte, J., Marozin, S., Schmid, R.M., and Ebert, O. (2010). Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 18, 275-284.
2. Bian, H., Wilden, H., Fournier, P., et al. (2006). In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int. J. Oncol. 29, 1359-1369.
3. Boisgerault, N., Tangy, F., and Gregoire, M. (2010). New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy 2, 185-199.
4. Cheng, T.F., Brzostek, S., Ando, O., et al. (2006). Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J. Immunol. 176, 7462-7470. (Pubitemid 43849049)
5. Collins, M.S., Bashiruddin, J.B., and Alexander, D.J. (1993). Deduced amino acid sequences at the fusion protein cleavage site of Newcastle disease viruses showing variation in antigenicity and pathogenicity. Arch. Virol. 128, 363-370.
6. Csatary, L.K., Gosztonyi, G., Szeberenyi, J., et al. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 67, 83-93. (Pubitemid 38418253)
7. de Leeuw, O.S., Hartog, L., Koch, G., and Peeters, B.P. (2003). Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: Non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J. Gen. Virol. 84, 475-484. (Pubitemid 36175724)
8. Eager, R.M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317.
9. ElaNKumaran, S., Chavan, V., Qiao, D., et al. (2010). Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol. 84, 3835-3844.
10. Feng, H., Wei, D., Nan, G., et al. (2011). Construction of a minigenome rescue system for Newcastle disease virus strain Italien. Arch. Virol. 156, 611-616.
11. Freeman, A.I., Zakay-Rones, Z., Gomori, J.M., et al. (2006). Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13, 221-228. (Pubitemid 41763501)
12. Ghosh, A.K., Majumder, M., Steele, R., et al. (2003). Modulation of interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1. Virology 306, 51-59. (Pubitemid 36293395)
13. Hotte, S.J., Lorence, R.M., Hirte, H.W., et al. (2007). An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 13, 977-985. (Pubitemid 46340376)
14. Huang, Z., Krishnamurthy, S., Panda, A., and Samal, S.K. (2001). High-level expression of a foreign gene from the most 3¢-proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 82, 1729-1736. (Pubitemid 32611515)
15. Huang, Z., ElaNKumaran, S., Panda, A., and Samal, S.K. (2003). Recombinant Newcastle disease virus as a vaccine vector. Poult. Sci. 82, 899-906. (Pubitemid 38641901)
16. Krishnamurthy, S., Takimoto, T., Scroggs, R.A., and Portner, A. (2006). Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80, 5145-5155.
17. Laurie, S.A., Bell, J.C., Atkins, H.L., et al. (2006). A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin. Cancer Res. 12, 2555-2562.
18. Lorence, R.M., Pecora, A.L., Major, P.P., et al. (2003). Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5, 618-624. (Pubitemid 38094433)
19. Lorence, R.M., Roberts, M.S., O'Neil, J.D., et al. (2007). Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7, 157-167. (Pubitemid 46348630)
20. Mansour, M., Palese, P., and Zamarin, D. (2011). Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015-6023.
21. Pecora, A.L., Rizvi, N., Cohen, G.I., et al. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251-2266. (Pubitemid 34441652)
22. Peeters, B.P., De Leeuw, O.S., Koch, G., and Gielkens, A.L. (1999). Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73, 5001-5009. (Pubitemid 29246761)
23. Prestwich, R.J., Harrington, K.J., Pandha, H.S., et al. (2008). Oncolytic viruses: A novel form of immunotherapy. Expert Rev. Anticancer Ther. 8, 1581-1588.
24. Reed, L.J., and Muench, H. (1938). A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
25. Vigil, A., Park, M.S., Martinez, O., et al. (2007). Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67, 8285-8292. (Pubitemid 47395166)
26. Vigil, A., Martinez, O., Chua, M.A., and Garcia-Sastre, A. (2008). Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16, 1883-1890.
27. Wang, N., Liang, Y., Devaraj, S., et al. (2009). Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83, 9824-9834.
28. Wei, D., Yang, B., Li, Y.L., et al. (2008). Characterization of the genome sequence of an oncolytic Newcastle disease virus strain Italien. Virus Res. 135, 312-319.
29. Wong, H.H., Lemoine, N.R., and Wang, Y. (2010). Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2, 78-106.
30. Zhao, H., and Peeters, B.P. (2003). Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol. 84, 781-788. (Pubitemid 36432208)